Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDX-060 in Refractory/Relapsed CD30 Lymphoma
NCT00059995Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2003
- Primary completion
- Oct 2007
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of iratumumab in Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL), sponsored by Memorial Sloan Kettering Cancer Center. Started Jan 2003; status: completed.
02
Drugs
iratumumab
03
Conditions
Hodgkin lymphoma (HL)anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on NCT00059995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00059995.